Illinois Health and Hospital Association

MEDICARE PAYMENT FACT SHEET

AUGUST 2021

CY 2022 MEDICARE OPPS PROPOSED RULE – CMS-1753-P

On Aug. 4, the Centers for Medicare & Medicaid Services (CMS) released its calendar year (CY) 2022 outpatient prospective payment system (OPPS) proposed rule. CMS estimates an overall increase in OPPS and Ambulatory Surgical Center (ASC) payments of 2.3% in calendar year (CY) 2022 compared with CY 2021. Comments are due Sept. 17.

CMS proposed using CY 2019 claims data to set CY 2022 rates. Normally, CMS uses the most recent complete year of claims data available for rate setting. However, CY 2020 is the most recent complete year of claims data, and CMS believes the COVID-19 public health emergency (PHE) significantly affected item and service access and utilization. Thus, CMS proposed forgoing its usual process and using CY 2019 claims data instead.

Price Transparency: CMS proposed several amendments and clarifications to the Hospital Price Transparency final rule, including:

1. Increasing civil monetary penalties (CMPs) for noncompliant hospitals;
2. Deeming state forensic hospitals meeting certain requirements as compliant;
3. Prohibiting the use of specific barriers to accessing the required machine-readable file; and
4. Clarifying output expectations for hospital online price estimator tools.

Under the price transparency final rule, CMS finalized CMPs of up to $300 per day for hospitals that fail to respond to or comply with corrective action plans for noncompliance. Due to a high rate of noncompliance, CMS proposed revising their CMP policy, suggesting a scaled CMP approach based on hospital bed count. The revised CMPs are as follows:

Number of Beds	Penalty per Day	Total Penalty per Calendar Year
30 or less	$300 per hospital	$109,500 per hospital
31 – 550	$310-$5,500 per hospital (number of beds x $10)	$113,150-$2,007,500 per hospital
More than 550	$5,500 per hospital	$2,007,500 per hospital

CMS seeks comments on these proposed changes, and invites submission of alternative scaling CMP methodologies.

Additionally, CMS proposed deeming state forensic hospitals meeting certain requirements as compliant with the price transparency final rule. CMS states that such hospitals have specialized patient populations, are not open to the general public, and do not negotiate their rates, and therefore should not be subject to price transparency requirements. In order to qualify for exemption, the hospital must provide treatment exclusively for individuals who are in the custody of penal authorities.

CMS also proposed amendments to address variability in how hospitals are making their machine-readable files publicly available. Specifically, CMS proposed amending the final rule to specify that hospitals must ensure that the machine-readable file is easily accessible and without

barriers. This includes, but is not limited to, ensuring that the file is accessible to automated searches and direct file downloads through a link posted on a publicly available website. CMS also seeks comments on whether stakeholders have identified additional barriers that should be prohibited, and whether there are specific criteria it should consider when evaluating whether a hospital has displayed the machine-readable file in a "prominent manner."

Regarding the required consumer-friendly file of shoppable services, CMS clarified the expected output of online price estimator tools. Specifically, the online price estimator tool must provide a cost estimate that accounts for the consumer's insurance information, and the estimate must reflect the amount the hospital anticipates will be paid by the consumer for the shoppable service, absent unusual or unforeseeable circumstances.

Finally, CMS seeks comment on a variety of other aspects to the Hospital Price Transparency final rule, including:

- Whether CMS should require specific plain language standards for the standard charges and shoppable services files;
- Whether CMS should highlight hospitals and their best practices that comply with price transparency requirements;
- How CMS might implement policies and requirements that result in better-standardized information across hospitals' machine readable files.

Temporary Policies Addressing the COVID-19 PHE: In response to the COVID-19 PHE, CMS issued several waivers and implemented temporary policies to provide greater flexibility to patients and providers and accessing and rendering medical care. These waivers and policies will expire at the end of the PHE, and CMS seeks comment on whether stakeholders utilized the flexibilities available under these waivers, and whether CMS should make certain policies permanent to the extent possible under its authority. Specifically, CMS seeks comments on the following:

- The extent to which hospitals have billed for mental health services provided to beneficiaries in their homes through communications technology during the PHE, and whether hospitals anticipate continuing demand for this model of care following the conclusion of the PHE;
- The extent to which hospitals used virtual presence through audio/video real-time communications technology to fulfill direct supervision requirements for pulmonary rehabilitation, cardiac rehabilitation, and intensive cardiac rehabilitation services, and whether CMS should continue to allow the provision of direct supervision for these services using audio/video real-time communications; and
- Whether CMS should keep HCPCS code C9803 (Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) and associated OPPS payments active beyond the conclusion of the COVID-19 PHE.

340B: CMS proposed continuing to pay for non-pass-through, separately payable drugs and biologicals acquired under the 340B program at average sales price (ASP) minus 22.5%, including when furnished at non-excepted off-campus provider based departments (PBDs).

This payment policy includes separately payable Medicare Part B drugs and biologicals (status indicator K), other than vaccines, and drugs with pass-through status when billed by OPPS hospitals that are not excepted from this payment adjustment. If there are not sufficient sales data, CMS will use wholesale acquisition cost (WAC), reimbursing providers at WAC minus 22.5%. If there are not sufficient wholesale cost data, CMS will use average wholesale price (AWP), and reimburse the provider at 69.46% of AWP.

Rural sole community hospitals, children's hospitals, and PPS-exempt cancer hospitals are exempt from this payment policy. Such providers must still append modifier "TB" on claims for drugs purchased through the 340B program, but CMS will pay the claim at ASP plus 6%. All non-exempt 340B hospitals must append the "JG" modifier to claims for drugs purchased through the 340B program.

Inpatient Only List (IPO): Prior to CY 2021, CMS used five criteria decide whether to remove a procedure from the IPO list. These criteria were:

1. Most outpatient departments are equipped to provide the service to the Medicare population.
2. The simplest procedure described by the code may be furnished in most outpatient departments.
3. The procedure is related to codes that were already removed from the IPO list.
4. CMS determines the procedure is being furnished in numerous hospitals on an outpatient basis.
5. CMS determines the procedure can be appropriately and safely furnished in an ASC and is on the ASC covered procedures list (CPL) or has been proposed by CMS for addition to the ASC CPL.

In CY 2021, CMS finalized the elimination of the IPO list over a three-year phase out period. Additionally, CMS moved away from using the above criteria, removing 298 codes from the IPO list beginning in CY 2021 without assessing them against these criteria. CMS justified this decision by pointing to the significant developments in the practice of medicine since establishing the IPO list, arguing these developments increased the safety and effectiveness of providing services in outpatient settings. CMS also stated that it expected providers to assess the risk of providing a procedure or service in an outpatient setting on a case-by-case basis, acting in the individual patient's best interest.

However, after reviewing additional comments and concerns, CMS is now proposing to halt the elimination of the IPO list, and to return the 298 removed codes to the IPO list beginning CY 2022. Further, CMS proposed codifying their five criteria for assessing the removal of codes from the IPO list (with a new §419.23). Comments opposed to removing the IPO list cited patient safety concerns, suggested the potential increased access to services was not worth the cost, and argued that the IPO list provides a common standard of medical judgement protecting Medicare beneficiaries. Further, CMS stated using removal criteria ensures a more gradual removal, allowing time for CMS and others to evaluate the safety of providing former IPO services in hospital outpatient departments. Finally, CMS reviewed CY 2020 data and found less than 3% of the 298 services/codes removed from the IPO list experienced notable utilization volume in outpatient settings, suggesting the outpatient setting may not be appropriate.

CMS seeks comments on keeping, but scaling back, the IPO list. Alternatively, CMS solicits comments on whether the agency should still eliminate the IPO list, but on a longer and more gradual timeline. Further, CMS asks stakeholders whether any of the 298 codes reinstated on the IPO list should, in fact, be removed.

Medical Review of Services Removed from IPO List: Procedures removed from the IPO list are subject to the 2-Midnight rule. In the CY 2020 OPPS/ASC final rule, CMS exempted procedures removed from the IPO list from certain medical review activities meant to assess compliance with the 2-Midnight rule within the 2 calendar years following their removal from the IPO list. Under the exemption, Beneficiary and Family-Centered Care Quality Improvement Organizations (BFCC-QIOs) could not consider recently removed procedures when determining whether a provider exhibits persistent noncompliance with the 2-Midnight rule for purposes of referral to a Recovery Audit Contractor (RAC). Additionally, RACs were not to review such procedures for "patient status" (i.e., site-of-service). BFCC-QIOs could still review relevant claims and educate practitioners and providers regarding compliance with the 2-Midnight rule, but claims identified as noncompliant would not be denied with respect to the site-of-service under Medicare Part A.

In CY 2021, CMS altered this policy, indefinitely exempting procedures removed from the IPO list after Jan. 1, 2021 from site-of-service claim denials under Medicare Part A, eligibility for BFCC-QIO referrals to RACs for noncompliance with the 2-Midnight rule, and RAC reviews for "patient status." The exemption would remain in place until there were enough Medicare claims data indicating that the outpatient setting was a more common site-of-service than the inpatient setting. Again, CMS allowed BFCC-QIOs the authority to review exempted claims in order to provide education for practitioners and providers regarding compliance with the 2-Midnight rule, but noncompliant claims were not denied with respect to the site of service under Medicare Part A. CMS maintained the ability to conduct medical reviews in cases where it believed there was potential fraud or abuse occurring.

In the CY 2022 proposed rule, and consistent with the decision to halt the elimination of the IPO list, CMS proposed reinstating the 2-year exemption from 2-Midnight medical review activities for services removed from the IPO list on or after Jan. 1, 2021. Additionally, CMS stressed it expects providers to continue using their complex medical judgment when deciding on the most appropriate site of service for an individual beneficiary, and to comply with the 2-Midnight rule. CMS seeks comments on this proposed policy reversal.

Coinsurance for Certain Colorectal Cancer Screenings: CMS used this proposed rule to implement coinsurance provisions specific to colorectal cancer screenings established in the Consolidated Appropriations Act (CAA). Starting Jan. 1, 2022, CMS will waive coinsurance for screening flexible sigmoidoscopies and screening colonoscopies. This policy applies to colorectal screenings regardless of eventual diagnosis, removal of tissue, or other matters or procedures furnished in connection with or resulting from the same clinical encounter as the screening test. CMS reminds providers that claims for colorectal screenings provided in the OPPS setting must include the modifier "PT."

OPPS Proposed Market Basket Update: CMS proposed a 2.5% market basket update and a 0.2 percentage point productivity reduction for OPPS payments, resulting in a 2.3% update to OPPS rates for hospitals that meet quality data submission requirements. These proposed

adjustments result in a CY 2022 conversion factor of $84.457. Hospitals that fail to submit quality data will be subject to a 2-percentage point reduction to payments, resulting in a conversion factor of $82.810.

Wage Index: CMS proposed continuing an OPPS labor-related share of 60%, and adopting the inpatient prospective payment system (IPPS) post reclassified wage index. The final CY 2022 OPPS wage index will reflect any adjustments made to the IPPS in the federal fiscal year (FFY) 2022 IPPS final rule.

Outlier Payments: To ensure CY 2022 aggregate outlier payments equal 1% of estimated total OPPS payments, CMS proposed outlier payments trigger when a hospital's cost of furnishing a service exceeds 1.75 times the Ambulatory Payment Classification (APC) payment amount. The proposed fixed-dollar loss amount for CY 2022 is $6,100 (up from $5,300 last year).

Sole Community Hospital (SCH) and Essential Access Community Hospital (EACH) Update: CMS proposed continuing its current policy of a 7.1% budget neutral payment adjustment for rural SCHs and EACHs for all OPPS services and procedures. This proposal excludes separately payable drugs and biologicals, brachytherapy sources, items paid at charges reduced to cost, and devices paid under the pass-through payment policy.

Payment for Drugs, Biologicals and Radiopharmaceuticals without Pass-Through Status: The proposed CY 2022 packaging threshold is $130.

Payment for Hospital Outpatient Visits and Critical Care Services: CMS proposed continuing its current clinic and emergency department (ED) hospital outpatient visit payment policies. Thus, CMS will continue utilizing the Medicare physician fee schedule-equivalent payment rate for hospital outpatient clinic visits (HCPCS code G0463) when furnished by excepted off-campus provider-based departments (PBDs). This results in a payment rate that is 60% less than the OPPS rate.

Hospital Outpatient Quality Reporting Program (OQR): CMS proposed several changes to the OQR program, including the proposed removal and replacement of two measures and three proposed additions.

The two measures CMS proposed removing beginning with the CY 2023 reporting period/CY 2025 payment determination include:

1. Fibrinolytic Therapy Received Within 30 Minutes of Emergency Department (ED) Arrival (OP-2); and
2. Median Time to Transfer to Another Facility for Acute Coronary Intervention.

CMS proposed replacing these two measure with a single electronic clinical quality measure (eCQM): ST-Segment Elevation Myocardial Infarction (STEMI). CMS indicated that the STEMI eCQM is an electronic process measure that includes both populations of OP-2 and OP-3. Additionally, providers can retrieve data for the STEMI eCQM directly from electronic health records (EHR) using patient-level data, while the OP-2 and OP-3 measures require manual chart-abstraction. STEMI eCQM reporting would be voluntary for the CY 2023 reporting period, and mandatory with the CY 2024 reporting period.

CMS proposed adopting two additional new measures for the OQR program:

1. COVID-19 Vaccination Coverage Among Health Care Personnel (HCP) beginning with the CY 2022 reporting period; and
2. Breast Screening Recall Rates beginning with the CY 2022 reporting period.

CMS also proposed modifications to a number of previously adopted measures, including:

- Restarting the collecting of the Outpatient and Ambulatory Surgery Consumer Assessment of Healthcare Providers and Systems (OAS CAHPS) survey-based measures (OP-37a-e) with voluntary reporting in CY 2023 and mandatory reporting in the CY 2024 reporting period/CY 2026 payment determination; and
- Requiring Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery (OP-31, NQF #1536) beginning with the CY 2023 reporting period/CY 2025 payment determination.

CMS presents previously finalized and proposed OQR measure sets in Table 46 (CY 2023 payment determination, *desk copy p. 558*), Table 47 (CY 2024 payment determination, *desk copy p. 559*), Table 48 (CY 2025 payment determination, *desk copy pp. 559-560*) and Table 49 (CY 2026 payment determination, *desk copy pp. 560-561*).

CMS also seeks comment on potential future measures, including measures that would:

- Allow better tracking of care quality for services removed from the IPO list;
- Provide a hospital-level, risk-standardized patient report outcomes measure following elective primary total hip and/or total knee arthroplasty (THA/TKA) measure; and
- Address health equity in the OQR program.

Regarding health equity, CMS solicits comments on expanding its current disparities methods to include reporting by race and ethnicity by using indirect estimation, having facilities collect standardized demographic information, and potentially designing a Facility Equity Score for presenting combined results across multiple social risk factors, including race/ethnicity and disability. CMS further identified six priority measures for disparities reporting stratified by dual eligibility, including:

- MRI Lumbar Spine for Low Back Pain (OP-8);
- Abdomen CT – Use of Contract Material (OP-10);
- Cardiac Imaging for Preoperative Risk Assessment for Non-Cardiac Low Risk Surgery (OP-13);
- Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy (OP-32);
- Admission and ED Visits for Patient Receiving Outpatient Chemotherapy (OP-35); and
- Hospital Visits after Hospital Outpatient Surgery (OP-36).

Finally, CMS proposed a progressive increase in the number of quarters for which hospital report eCQM data, starting with limited voluntary reporting to give hospitals time to gain experience implementing eCQMs, provide training, and gain reporting experience. The proposed timeline is below (Table 51, *desk copy p. 593*):

Calendar Year Period	Calendar Quarters of Reporting	Reporting
CY 2023 Reporting Period/CY 2025 Payment Determination	Any quarter(s)	Voluntary
CY 2024 Reporting Period/CY 2026 Payment Determination	One self-selected quarter	Mandatory
CY 2025 Reporting Period/CY 2027 Payment Determination	Two-self-selected quarters	Mandatory
CY 2026 Reporting Period/CY 2028 Payment Determination	Three self-selected quarters	Mandatory
CY 2027 Reporting Period/CY 2029 Payment Determination and Subsequent Years	Four quarters (one calendar year)	Mandatory

Proposed Partial Hospitalization Program (PHP) and Community Mental Health Center (CMHC) Updates: For CY 2022 only, CMS proposed hospital-based PHP and CMHC geometric mean per diem rates at the greater of the CY 2021 geometric mean per diem cost, or the calculated CY 2022 geometric mean per diem cost based on CY 2019 claims and CY 2021 cost data.

The CY 2021 geometric mean per diem costs are $253.76 for hospital-based PHPs and $136.14 for CMHCs. The calculated CY 2022 geometric mean per diem costs are $253.08 for hospital-based PHPs and $130.41 for CMHCs. Therefore, CMS proposed using the CY 2021 geometric mean per diem costs unless final calculated rates end up exceeding these rates.

CMS proposed to continue applying the 8% CMHC outlier payment cap to CMHC total per diem payments.

ASC Proposed Market Basket Update: CMS proposed a 2.5% market basket update and a 0.2 percentage point productivity reduction for ASC payments, resulting in a 2.3% update to CY 2020 rates for ASCs. These proposed adjustments result in a CY 2022 conversion factor of $50.043. ASCs that fail to submit quality data will be subject to a 2-percentage point reduction to payments, resulting in a conversion factor of $49.064.

Per a MedPAC recommendation, CMS solicits comments on methods that would mitigate the burden of reporting ASC costs while ensuring the collection of enough data to reliably determine ASC costs in the future.

ASC Covered Procedure List (CPL): Aligning with the proposed halt in eliminating the IPO list, CMS proposed reinstating specifications for adding surgical procedures to the ASC covered procedures list that were in place prior to CY 2021. These specifications state that ASC CPL services furnished on or after Jan. 1, 2022 are those specified by the Secretary of Health and Human Services (HHS) and published in the *Federal Register* and/or via CMS' website. These procedures should not pose a significant safety risk to a Medicare beneficiary when performed in an ASC, and standard medical practice should dictate that the beneficiary would not typically require active medical monitoring and care at midnight following the procedure. The ASC CPL would not include procedures that:

- Generally result in extensive blood loss;
- Require major or prolonged invasion of body cavities;
- Directly involve major blood vessels;
- Are generally emergent or life threatening in nature;
- Commonly require systemic thrombolytic therapy;
- Are designated as requiring inpatient care under § 419.22(n);
- Can only be reported using a CPT unlisted surgical procedure code; or

- Are otherwise excluded under § 411.15.

Additionally, CMS solicits comments on procedures added to the ASC CPL in CY 2021 but would not meet these proposed revised CY 2022 criteria (see Table 45, *desk copy pp. 465-478*).

ASC Quality Reporting Program (ASCQR): CMS proposed adopting the COVID-19 Vaccination Coverage among Health Care Personnel (HCP) measure beginning with the CY 2022 reporting period/CY 2024 payment determination. CMS also proposed requiring reporting on previously suspended measures including:

- ASC-1: Patient Burn beginning with the CY 2023 reporting period/CY 2025 payment determination;
- ASC-2: Patient Fall (NQF #0266) beginning with the CY 2023 reporting period/CY 2025 payment determination;
- ASC-3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant (NQF #0267) beginning with the CY 2023 reporting period/CY 2025 payment determination;
- ASC-4: All-Cause Hospital Transfer/Admission (NQF #0265) beginning with the CY 2023 reporting period/CY 2025 payment determination;
- ASC-11: Cataracts – Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery (NQF #1536) beginning with the CY 2023 reporting period/CY 2025 payment determination; and
- ASC-15a-e: Outpatient and Ambulatory Surgery Consumer Assessment of Healthcare Providers and Systems (OAS CAHPS) Survey-Based Measures (voluntary reporting CY 2023, mandatory reporting beginning with CY 2024 reporting period/CY 2026 payment determination).

Previously finalized and proposed ASCQR program quality measure sets are in Table 52 (CY 2024 payment determination, *desk copy p. 635*), Table 53 (CY 2025 payment determination, *desk copy p. 635*) and Table 54 (CY 2026 payment determination, *desk copy p. 636*). CMS seeks comments on future measures to address care quality for procedures transitioning off the IPO list; potential future adoption and inclusion of an ASC-level risk-standardized patient reported outcomes measure following elective THA/TKA; potential future efforts to address health equity in the ASCQR program; and future development and inclusion of a pain management measure in the ASCQR.

Rural Emergency Hospitals: In the CAA, Congress established a new Medicare provider type: Rural Emergency Hospitals (REHs). The CAA defines REHs as a facility that:

- Is enrolled in Medicare on or after Jan. 1, 2023;
- Does not provide any acute care inpatient services (other than post-hospital extended care services furnished in a distinct part unit licensed as a skilled nursing facility);
- Has a transfer agreement in effect with a level I or level II trauma center;
- Meets certain licensure requirements;
- Meets requirements to be a staffed emergency department;
- Meets staff training and certification requirements established by the Secretary of HHS; and

- Meets certain conditions of Participation applicable to hospital emergency departments and critical access hospitals (CAHs) with respect to emergency services.

CAHs and small rural hospitals that convert to REHs may furnish rural emergency hospital services for Medicare payment beginning in 2023.

In this proposed rule, CMS solicits stakeholder input on health and safety standards that should apply to REHs participating in the Medicare program. CMS posed specific questions on the type and scope of services offered; health and safety standards, including licensure and conditions of participation; health equity; collaboration and care coordination; quality measurement; payment provisions; and the enrollment process.

Digital Quality Measurement and use of FHIR® in Hospital Quality Programs: CMS requested information on policies meant to move further toward its goal of fully digitizing quality measurement by 2025. Specifically, CMS seeks feedback on the following:

- A proposed definition of digital quality measures (dQMs) as quality measures calculated using digital data from one or more sources of data including, but not limited to, administrative systems, electronically submitted clinical assessment data, case management systems, EHRs, instruments, patient portals or applications, health information exchanges or registries; where dQMs are intended to improve the patient experience including quality of care, improve the health of populations, and/or reduce costs;
- Use of FHIR® as a framework for measure structure and data submission for current electronic clinical quality measures (eCQMs); and
- Feedback on a number of data issues, including how CMS can better support data aggregation and aligning measure requirements across Medicare reporting programs and other Federal programs and agencies.

Radiation Oncology Model: The Radiation Oncology (RO) Model tests whether prospective episode-based payments for radiotherapy (RT) services will reduce Medicare program expenditures and preserve or enhance quality of care for beneficiaries. The CAA delayed the start of the RO Model due to the COVID-19 pandemic.

In accordance with the CAA, CMS proposed beginning the RO Model on Jan. 1, 2022, modifying the model performance period to begin on Jan. 1, 2022 and end Dec. 31, 2026. CMS also proposed that each performance year will be a 12-month period beginning on Jan. 1 and ending on Dec. 31 of each year during the performance period, unless the initial model performance period starts mid-year, in which case performance year 1 will begin on that date and end on Dec. 31 of that year. CMS also proposed and solicits public comment on several RO Model definitions. Excluded from the RO Model are ASCs and CAHs, and CMS proposed to further exclude any Hospital Outpatient Department participating in the Community Health Access and Rural Transformation (CHART) Model.

Additionally, CMS proposed specific criteria for including a type of cancer in the RO Model. Liver cancer does not meet these criteria. As such, CMS proposed removing liver cancer from the included cancer types. CMS also proposed removing brachytherapy as an included modality in the RO Model as commenters suggested including it may disincentivize utilization of

brachytherapy. Table 56 (*desk copy pp. 691-692*) lists HCPCS codes for the RO Model bundles, Table 57 (*desk copy p. 696*) lists the cancer types included in the RO Model and their corresponding ICD-10 codes, and Table 58 (*desk copy pp. 700-701*) includes the proposed national base rates for the model performance period, which are based on the criteria set forth for cancer type inclusion. For more information, see the full text of the CY 2022 OPPS proposed rule and the RO Model website.

Contact IHA

Sources:

Centers for Medicare & Medicaid Services. Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Price Transparency of Hospital Standard Charges; Radiation Oncology Model; Request for Information on Rural Emergency Hospitals. Available from: https://www.federalregister.gov/public-inspection/2021-15496/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment. Accessed July 30, 2021.